BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance

by Ryan J. Sullivan, Keith T. Flaherty
Published 2011-01-01

A melanoma molecular disease model.

by Smruti J Vidwans, Keith T Flaherty, David E Fisher, Jay M Tenenbaum, Michael D Travers, Jeff Shrager
Published 2011-03-01

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled a...

by Paolo A. Ascierto, Antoni Ribas, James Larkin, Grant A. McArthur, Karl D. Lewis, Axel Hauschild, Keith T. Flaherty, Edward McKenna, Qian Zhu, Yong Mun, Brigitte Dréno
Published 2020-08-01

The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling.

by Brijal M Desai, Jessie Villanueva, Thierry-Thien K Nguyen, Mercedes Lioni, Min Xiao, Jun Kong, Clemens Krepler, Adina Vultur, Keith T Flaherty, Katherine L Nathanson, Keiran S M Smalley, Meenhard Herlyn
Published 2013-01-01

Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel.

by Lucia B Jilaveanu, Fengmin Zhao, Christopher R Zito, John M Kirkwood, Katherine L Nathanson, Kurt D'Andrea, Melissa Wilson, David L Rimm, Keith T Flaherty, Sandra J Lee, Harriet M Kluger
Published 2013-01-01

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma

by Meghan J. Mooradian, Alexandre Reuben, Peter A. Prieto, Mehlika Hazar-Rethinam, Dennie T. Frederick, Brandon Nadres, Adriano Piris, Vikram Juneja, Zachary A. Cooper, Arlene H. Sharpe, Ryan B. Corcoran, Keith T. Flaherty, Donald P. Lawrence, Jennifer A. Wargo, Ryan J. Sullivan
Published 2018-05-01

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation

by Ester Simeone, Giosuè Scognamiglio, Mariaelena Capone, Diana Giannarelli, Antonio M. Grimaldi, Domenico Mallardo, Gabriele Madonna, Marcello Curvietto, Assunta Esposito, Fabio Sandomenico, Francesco Sabbatino, Nicholas L. Bayless, Sarah Warren, SuFey Ong, Gerardo Botti, Keith T. Flaherty, Soldano Ferrone, Paolo A. Ascierto
Published 2021-01-01

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.

by Adam A Friedman, Arnaud Amzallag, Iulian Pruteanu-Malinici, Subash Baniya, Zachary A Cooper, Adriano Piris, Leeza Hargreaves, Vivien Igras, Dennie T Frederick, Donald P Lawrence, Daniel A Haber, Keith T Flaherty, Jennifer A Wargo, Sridhar Ramaswamy, Cyril H Benes, David E Fisher
Published 2015-01-01

An active learning approach for rapid characterization of endothelial cells in human tumors.

by Raghav K Padmanabhan, Vinay H Somasundar, Sandra D Griffith, Jianliang Zhu, Drew Samoyedny, Kay See Tan, Jiahao Hu, Xuejun Liao, Lawrence Carin, Sam S Yoon, Keith T Flaherty, Robert S Dipaola, Daniel F Heitjan, Priti Lal, Michael D Feldman, Badrinath Roysam, William M F Lee
Published 2014-01-01

Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.

by Dennie T Frederick, Roberto A Salas Fragomeni, Aislyn Schalck, Isabel Ferreiro-Neira, Taylor Hoff, Zachary A Cooper, Rizwan Haq, David J Panka, Lawrence N Kwong, Michael A Davies, James C Cusack, Keith T Flaherty, David E Fisher, James W Mier, Jennifer A Wargo, Ryan J Sullivan
Published 2014-01-01

Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation

by Hyungsoo Kim, Dennie T. Frederick, Mitchell P. Levesque, Zachary A. Cooper, Yongmei Feng, Clemens Krepler, Laurence Brill, Yardena Samuels, Nicholas K. Hayward, Ally Perlina, Adriano Piris, Tongwu Zhang, Ruth Halaban, Meenhard M. Herlyn, Kevin M. Brown, Jennifer A. Wargo, Reinhard Dummer, Keith T. Flaherty, Ze’ev A. Ronai
Published 2015-06-01

Isolation and Molecular Characterization of Circulating Melanoma Cells

by Xi Luo, Devarati Mitra, Ryan J. Sullivan, Ben S. Wittner, Anya M. Kimura, Shiwei Pan, Mai P. Hoang, Brian W. Brannigan, Donald P. Lawrence, Keith T. Flaherty, Lecia V. Sequist, Martin McMahon, Marcus W. Bosenberg, Shannon L. Stott, David T. Ting, Sridhar Ramaswamy, Mehmet Toner, David E. Fisher, Shyamala Maheswaran, Daniel A. Haber
Published 2014-05-01

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance

by Julia Boshuizen, David W. Vredevoogd, Oscar Krijgsman, Maarten A. Ligtenberg, Stephanie Blankenstein, Beaunelle de Bruijn, Dennie T. Frederick, Juliana C. N. Kenski, Mara Parren, Marieke Brüggemann, Max F. Madu, Elisa A. Rozeman, Ji-Ying Song, Hugo M. Horlings, Christian U. Blank, Alexander C. J. van Akkooi, Keith T. Flaherty, Genevieve M. Boland, Daniel S. Peeper
Published 2020-08-01

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence

by Katherine R. Singleton, Lorin Crawford, Elizabeth Tsui, Haley E. Manchester, Ophelia Maertens, Xiaojing Liu, Maria V. Liberti, Anniefer N. Magpusao, Elizabeth M. Stein, Jennifer P. Tingley, Dennie T. Frederick, Genevieve M. Boland, Keith T. Flaherty, Shannon J. McCall, Clemens Krepler, Katrin Sproesser, Meenhard Herlyn, Drew J. Adams, Jason W. Locasale, Karen Cichowski, Sayan Mukherjee, Kris C. Wood
Published 2017-12-01

Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma

by Ileabett M Echevarría‐Vargas, Patricia I Reyes‐Uribe, Adam N Guterres, Xiangfan Yin, Andrew V Kossenkov, Qin Liu, Gao Zhang, Clemens Krepler, Chaoran Cheng, Zhi Wei, Rajasekharan Somasundaram, Giorgos Karakousis, Wei Xu, Jennifer JD Morrissette, Yiling Lu, Gordon B Mills, Ryan J Sullivan, Miao Benchun, Dennie T Frederick, Genevieve Boland, Keith T Flaherty, Ashani T Weeraratna, Meenhard Herlyn, Ravi Amaravadi, Lynn M Schuchter, Christin E Burd, Andrew E Aplin, Xiaowei Xu, Jessie Villanueva
Published 2018-05-01

SARS-CoV-2 viral load is associated with increased disease severity and mortality

by Jesse Fajnzylber, James Regan, Kendyll Coxen, Heather Corry, Colline Wong, Alexandra Rosenthal, Daniel Worrall, Francoise Giguel, Alicja Piechocka-Trocha, Caroline Atyeo, Stephanie Fischinger, Andrew Chan, Keith T. Flaherty, Kathryn Hall, Michael Dougan, Edward T. Ryan, Elizabeth Gillespie, Rida Chishti, Yijia Li, Nikolaus Jilg, Dusan Hanidziar, Rebecca M. Baron, Lindsey Baden, Athe M. Tsibris, Katrina A. Armstrong, Daniel R. Kuritzkes, Galit Alter, Bruce D. Walker, Xu Yu, Jonathan Z. Li, The Massachusetts Consortium for Pathogen Readiness
Published 2020-10-01

Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines

by Bradley Garman, Ioannis N. Anastopoulos, Clemens Krepler, Patricia Brafford, Katrin Sproesser, Yuchao Jiang, Bradley Wubbenhorst, Ravi Amaravadi, Joseph Bennett, Marilda Beqiri, David Elder, Keith T. Flaherty, Dennie T. Frederick, Tara C. Gangadhar, Michael Guarino, David Hoon, Giorgos Karakousis, Qin Liu, Nandita Mitra, Nicholas J. Petrelli, Lynn Schuchter, Batool Shannan, Carol L. Shields, Jennifer Wargo, Brandon Wenz, Melissa A. Wilson, Min Xiao, Wei Xu, Xaiowei Xu, Xiangfan Yin, Nancy R. Zhang, Michael A. Davies, Meenhard Herlyn, Katherine L. Nathanson
Published 2017-11-01

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

by Moshe Sade-Feldman, Yunxin J. Jiao, Jonathan H. Chen, Michael S. Rooney, Michal Barzily-Rokni, Jean-Pierre Eliane, Stacey L. Bjorgaard, Marc R. Hammond, Hans Vitzthum, Shauna M. Blackmon, Dennie T. Frederick, Mehlika Hazar-Rethinam, Brandon A. Nadres, Emily E. Van Seventer, Sachet A. Shukla, Keren Yizhak, John P. Ray, Daniel Rosebrock, Dimitri Livitz, Viktor Adalsteinsson, Gad Getz, Lyn M. Duncan, Bo Li, Ryan B. Corcoran, Donald P. Lawrence, Anat Stemmer-Rachamimov, Genevieve M. Boland, Dan A. Landau, Keith T. Flaherty, Ryan J. Sullivan, Nir Hacohen
Published 2017-10-01

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma

by Clemens Krepler, Katrin Sproesser, Patricia Brafford, Marilda Beqiri, Bradley Garman, Min Xiao, Batool Shannan, Andrea Watters, Michela Perego, Gao Zhang, Adina Vultur, Xiangfan Yin, Qin Liu, Ioannis N. Anastopoulos, Bradley Wubbenhorst, Melissa A. Wilson, Wei Xu, Giorgos Karakousis, Michael Feldman, Xiaowei Xu, Ravi Amaravadi, Tara C. Gangadhar, David E. Elder, Lauren E. Haydu, Jennifer A. Wargo, Michael A. Davies, Yiling Lu, Gordon B. Mills, Dennie T. Frederick, Michal Barzily-Rokni, Keith T. Flaherty, Dave S. Hoon, Michael Guarino, Joseph J. Bennett, Randall W. Ryan, Nicholas J. Petrelli, Carol L. Shields, Mizue Terai, Takami Sato, Andrew E. Aplin, Alexander Roesch, David Darr, Steve Angus, Rakesh Kumar, Ensar Halilovic, Giordano Caponigro, Sebastien Jeay, Jens Wuerthner, Annette Walter, Matthias Ocker, Matthew B. Boxer, Lynn Schuchter, Katherine L. Nathanson, Meenhard Herlyn
Published 2017-11-01

Opportunities and challenges in oncology targeted drug development : an assessment of the use of prevalence and companion diagnostic performance thresholds to guide clinical trial...

by Vital, Heather Stacey Tomkinson
Published 2013